Johnson & Johnson
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
55.58%
Market Cap
506.84 Bil.
P/E Ratio
18.82
Dividend Yield
2.48 %
Earnings per Share
9.78 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 210.55 G | 0 Units |
| PRICE DETERMINATION TIME | 06/23/2026 / 09:56:48 PM | |
| DAILY VOLUME (UNITS) | 216 | |
| DAILY HIGH / LOW | 210.55 | 202.6 |
| PREV. DAY'S PRICE | 202.25 | (06/22) |
| CHANGE DAY BEFORE | +8.30 | 4.10 % |
| 52 WEEK HIGH / LOW | 214.3 (04/02) | 128.94 (06/30) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 11.07 | 10.09 | 9.78 | 5.35 | 5.12 |
| DIVIDENDS PER SHARE | 4.82 | 4.64 | 4.56 | 4.54 | 4.35 |
| DIVIDEND YIELD IN % | - | - | 2.48 % | 3.39 % | 3.00 % |
| DIVIDEND GROWTH IN % | - | - | 0.37 % | 4.41 % | 2.73 % |
| PRICE - EARNINGS RATIO | 17.99 | 19.74 | 18.82 | 25.05 | 28.32 |
| PRICE - BOOK RATIO | - | - | 6.13 | 4.88 | 5.49 |
| PRICE - SALES RATIO | - | - | 5.36 | 3.97 | 4.71 |
| PRICE - CASH FLOW RATIO | - | - | 20.56 | 14.52 | 17.61 |
Master Data
| WKN | 853260 |
| ISIN | US4781601046 |
| SYMBOL | JNJ |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Johnson & Johnson |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 2.41 Bil. |
| MARKET CAPITALISATION | 506.84 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -0.52 % | 0.12 % | -0.69 % | 14.65 % | 55.58 % | 34.03 % | 47.54 % | 14.56 % |
| HIGH | 204.05 | 209.45 | 214.30 | 214.30 | 214.30 | 214.30 | 214.30 | 214.30 |
| LOW | 197.44 | 190.64 | 187.12 | 172.04 | 128.94 | 127.88 | 127.88 | 172.04 |
Dividend
per share
Company profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Structured products for Johnson & Johnson
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.